tradingkey.logo

Aclarion Inc

ACON
查看詳細走勢圖
2.750USD
+0.390+16.53%
收盤 02/06, 16:00美東報價延遲15分鐘
1.60M總市值
虧損本益比TTM

Aclarion Inc

2.750
+0.390+16.53%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+16.53%

5天

-16.92%

1月

-52.17%

6月

-62.38%

今年開始到現在

-40.22%

1年

-98.10%

查看詳細走勢圖

TradingKey Aclarion Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Aclarion Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名202/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為23.00。中期看,股價處於下降通道。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Aclarion Inc評分

相關信息

行業排名
202 / 392
全市場排名
393 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Aclarion Inc亮點

亮點風險
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
業績增長期
公司處於發展階段,最新年度總收入45.72K美元
估值高估
公司最新PE估值-0.00,處於3年歷史高位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉6.78K股

分析師目標

基於 1 分析師
買入
評級
23.000
目標均價
+751.85%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Aclarion Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Aclarion Inc簡介

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
公司代碼ACON
公司Aclarion Inc
CEONess (Brent)
網址https://aclarion.com/
KeyAI